GH Research (GHRS) Return on Capital Employed (2021 - 2025)
GH Research's (GHRS) quarterly Return on Capital Employed came in at 21.17% in Q4 2025, up 602.0% year-on-year from 3.02% in Q4 2024, and down 10.56% quarter-over-quarter from 19.15% in Q3 2025.
GH Research (GHRS) Return on Capital Employed (2021 - 2025) Analysis & Trends
GH Research's Return on Capital Employed history runs 5 years deep, the most recent figure standing at 21.17% for Q4 2025.
- On a quarterly basis, Return on Capital Employed rose 602.0% year-over-year to 21.17% in Q4 2025; TTM through Dec 2025 was 21.17%, a 602.0% increase from a year earlier, with the FY2025 full-year figure at 26.41%, down 105.0% from the prior year.
- Return on Capital Employed retreated to 21.17% in Q4 2025 per GHRS's latest filing, from 19.15% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 5.33% in Q4 2021 and bottomed at 27.2% in Q4 2024.
- The 5-year median for Return on Capital Employed is 17.27% (2025), against an average of 16.65%.
- Across the five-year window, Return on Capital Employed tumbled 869 bps in 2024 and jumped 602 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 5.33% in 2021, then tumbled by 127 bps to 12.09% in 2022, then tumbled by 53 bps to 18.51% in 2023, then plunged by 47 bps to 27.2% in 2024, then climbed by 22 bps to 21.17% in 2025.
- Per Business Quant, the three latest GHRS Return on Capital Employed figures stand at 21.17% (Q4 2025), 19.15% (Q3 2025), and 17.27% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | GH Research | 1.69 Bn | 1.69 Bn | - | -21.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -21.17% |
| Sep 30, 2025 | -19.15% |
| Jun 30, 2025 | -17.27% |
| Mar 31, 2025 | -21.07% |
| Dec 31, 2024 | -27.20% |
| Sep 30, 2024 | -25.08% |
| Jun 30, 2024 | -22.31% |
| Mar 31, 2024 | -19.72% |
| Dec 31, 2023 | -18.51% |
| Sep 30, 2023 | -17.04% |
| Jun 30, 2023 | -15.17% |
| Mar 31, 2023 | -13.45% |
| Dec 31, 2022 | -12.09% |
| Sep 30, 2022 | -10.78% |
| Jun 30, 2022 | -9.76% |
| Mar 31, 2022 | -7.94% |
| Dec 31, 2021 | -5.33% |